Lenalidomide for del(5q) LR-MDS

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-LENALIDOMIDE`

ID	`REG-LENALIDOMIDE-MDS-DEL5Q`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-MDS-2021` `SRC-MDS-004-FENAUX-2011` `SRC-NCCN-AML-2025`

Notes

Standard for transfusion-dependent del(5q) LR-MDS. ~56% achieve RBC transfusion independence (MDS-004); ~20-25% achieve cytogenetic CR (loss of del(5q) clone). Mandatory pregnancy prevention (REMS/Revlimid programme). VTE prophylaxis mandatory. Avoid combination with ESA. STUB — pending Co-Lead sign-off.

Used By

Indication

IND-MDS-LR-LENALIDOMIDE-DEL5Q - IND-MDS-LR-LENALIDOMIDE-DEL5Q